Zheng Quan Shi Bao·2025-12-18 18:09Core Viewpoint - Fosun Pharma has signed a collaboration and option agreement with Clavis Bio to jointly select targets and advance preclinical development of selected compounds, with potential payments of up to $363 million for each project [1][2]. Group 1: Collaboration Details - The agreement allows Fosun Pharma to collaborate with Clavis Bio on selected targets, with Clavis Bio holding exclusive global rights for development, production, and commercialization outside of mainland China, Hong Kong, and Macau [1]. - Fosun Pharma can receive up to $363 million in payments for each selected project, which includes non-refundable option fees, development milestone payments, and sales milestone payments [1]. - Additionally, Fosun Pharma will receive a minority equity stake in a new company established by Clavis Bio's parent fund, Aditum Bio Fund3, at no cost [1]. Group 2: Company Background - Clavis Bio was established in March 2025 and is a wholly-owned subsidiary of Aditum Bio, which focuses on venture capital in the biotechnology sector [2]. - Aditum Bio was co-founded in 2019 by former Novartis CEO Joe Jimenez and former director of the Novartis Biomedical Research Institute Mark Fishman, aiming to accelerate drug development for unmet clinical needs [2]. Group 3: Strategic Implications - The collaboration is intended to leverage the research strengths of both parties, enriching Fosun Pharma's high-value product pipeline and potentially accelerating global clinical development and commercialization of related pipelines [2]. - Fosun Pharma is also pursuing acquisitions to enhance its drug pipeline, as evidenced by its recent announcement to acquire a controlling stake in Green Valley Pharmaceutical for 1.412 billion yuan to obtain its core drug, which treats mild to moderate Alzheimer's disease [3].